Trending NewsTrending NewsNASDAQ:CRDF Cardiff Oncology (CRDF) Stock Price, News & Analysis $2.64 +0.27 (+11.39%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.66 +0.02 (+0.61%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cardiff Oncology Stock (NASDAQ:CRDF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cardiff Oncology alerts:Sign Up Key Stats Today's Range$2.39▼$2.7950-Day Range$2.37▼$4.4552-Week Range$2.01▼$5.64Volume5.87 million shsAverage Volume2.75 million shsMarket Capitalization$175.64 millionP/E RatioN/ADividend YieldN/APrice Target$11.70Consensus RatingModerate Buy Company Overview Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Read More Cardiff Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreCRDF MarketRank™: Cardiff Oncology scored higher than 35% of companies evaluated by MarketBeat, and ranked 724th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingCardiff Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCardiff Oncology has only been the subject of 4 research reports in the past 90 days.Read more about Cardiff Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cardiff Oncology are expected to grow in the coming year, from ($0.99) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiff Oncology is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiff Oncology is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiff Oncology has a P/B Ratio of 3.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cardiff Oncology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.41% of the outstanding shares of Cardiff Oncology have been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 15.6, which indicates bearish sentiment.Change versus previous monthShort interest in Cardiff Oncology has recently increased by 2.83%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCardiff Oncology does not currently pay a dividend.Dividend GrowthCardiff Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted28.41% of the outstanding shares of Cardiff Oncology have been sold short.Short Interest Ratio / Days to CoverCardiff Oncology has a short interest ratio ("days to cover") of 15.6, which indicates bearish sentiment.Change versus previous monthShort interest in Cardiff Oncology has recently increased by 2.83%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment0.48 News SentimentCardiff Oncology has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Cardiff Oncology this week, compared to 2 articles on an average week.Search Interest10 people have searched for CRDF on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Cardiff Oncology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $710,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Cardiff Oncology is held by insiders.Percentage Held by InstitutionsOnly 16.29% of the stock of Cardiff Oncology is held by institutions.Read more about Cardiff Oncology's insider trading history. Receive CRDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDF Stock News HeadlinesGary W. Pace Buys 15,000 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) StockAugust 1 at 6:26 AM | insidertrades.comCardiff Oncology Insiders Land Bargain With Gains Of US$244kJuly 31 at 6:31 AM | finance.yahoo.comMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alternative Assets reveals 3 urgent moves to protect your portfolio, plus the #1 asset class thriving during crises (hint: it’s not stocks or bonds). | American Alternative (Ad)Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business UpdateJuly 31 at 6:31 AM | finance.yahoo.comCardiff Oncology (CRDF) Q2 Loss Down 19%July 30 at 6:36 PM | fool.comWhy Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?July 30 at 3:27 PM | benzinga.comCardiff Oncology: Data Update Resolves Some SignalsJuly 30 at 12:15 PM | seekingalpha.comCardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)July 29, 2025 | globenewswire.comSee More Headlines CRDF Stock Analysis - Frequently Asked Questions How have CRDF shares performed this year? Cardiff Oncology's stock was trading at $4.34 at the beginning of 2025. Since then, CRDF stock has decreased by 39.2% and is now trading at $2.64. How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:CRDF) posted its quarterly earnings data on Tuesday, July, 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.11 million. Cardiff Oncology had a negative net margin of 9,344.14% and a negative trailing twelve-month return on equity of 77.94%. Who are Cardiff Oncology's major shareholders? Cardiff Oncology's top institutional investors include Blair William & Co. IL (3.79%), SteelPeak Wealth LLC (0.03%) and Baader Bank Aktiengesellschaft (0.02%). Insiders that own company stock include Gary W Pace, Lale White, James E Levine and Mark Erlander. View institutional ownership trends. How do I buy shares of Cardiff Oncology? Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include NVIDIA (NVDA), CrowdStrike (CRWD), Digital Turbine (APPS), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings7/29/2025Today8/01/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRDF CIK1213037 Webcardiffoncology.com Phone(858) 952-7570FaxN/AEmployees20Year Founded1999Price Target and Rating Average Price Target for Cardiff Oncology$11.70 High Price Target$19.00 Low Price Target$3.50 Potential Upside/Downside+343.2%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.43 million Net Margins-9,344.14% Pretax Margin-9,344.14% Return on Equity-77.94% Return on Assets-63.65% Debt Debt-to-Equity RatioN/A Current Ratio4.42 Quick Ratio6.22 Sales & Book Value Annual Sales$545 thousand Price / Sales322.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book3.00Miscellaneous Outstanding Shares66,526,000Free Float61,403,000Market Cap$175.63 million OptionableOptionable Beta1.52 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:CRDF) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.